SG Americas Securities LLC Sells 8,100 Shares of Haemonetics Co. (NYSE:HAE)

SG Americas Securities LLC decreased its position in shares of Haemonetics Co. (NYSE:HAE) by 82.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 1,732 shares of the medical instruments supplier’s stock after selling 8,100 shares during the quarter. SG Americas Securities LLC’s holdings in Haemonetics were worth $135,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. FMR LLC boosted its holdings in Haemonetics by 206.3% in the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock valued at $62,257,000 after purchasing an additional 521,640 shares during the period. Wellington Management Group LLP boosted its stake in shares of Haemonetics by 9.5% in the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock valued at $337,722,000 after buying an additional 363,702 shares during the period. Allspring Global Investments Holdings LLC grew its position in Haemonetics by 75.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 795,381 shares of the medical instruments supplier’s stock worth $63,933,000 after buying an additional 343,214 shares in the last quarter. Thrivent Financial for Lutherans increased its stake in Haemonetics by 29.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock worth $88,433,000 after acquiring an additional 250,833 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in Haemonetics by 439.9% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 220,453 shares of the medical instruments supplier’s stock valued at $17,720,000 after acquiring an additional 179,621 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on HAE. Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and dropped their price target for the company from $95.00 to $68.00 in a research note on Friday. Barrington Research dropped their target price on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday. Raymond James reiterated a “strong-buy” rating and set a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a research report on Friday. Needham & Company LLC lowered their price objective on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research report on Friday. Finally, JMP Securities reduced their target price on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a report on Friday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Haemonetics has an average rating of “Moderate Buy” and a consensus price target of $101.67.

Haemonetics Trading Up 2.0 %

Shares of HAE stock opened at $60.51 on Tuesday. The business has a 50-day moving average of $76.38 and a 200 day moving average of $78.22. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.09. Haemonetics Co. has a 1-year low of $58.80 and a 1-year high of $97.97. The stock has a market capitalization of $3.04 billion, a PE ratio of 23.82, a P/E/G ratio of 0.98 and a beta of 0.39.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, sell-side analysts anticipate that Haemonetics Co. will post 4.59 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.